Amphastar Pharmaceuticals has scored a first in the US, after the US Food and Drug Administration approved the firm’s abbreviated new drug application for a generic glucagon for injection emergency kit, 1mg.
The firm said it planned to launch the diabetes product – previously referred to under the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?